



Corrigendum: Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response

Mark B. Carascal^{1,2†}, Rance Derrick N. Pavon^{1†} and Windell L. Rivera^{1*}

OPEN ACCESS

Edited and reviewed by:

Huan Nguyen,
IGY Life Sciences, Canada

*Correspondence:

Windell L. Rivera
wlrivera@science.upd.edu.ph

[†]These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Viral Immunology,
a section of the journal
Frontiers in Immunology

Received: 19 May 2022

Accepted: 24 May 2022

Published: 13 June 2022

Citation:

Carascal MB, Pavon RDN
and Rivera WL (2022)

Corrigendum: Recent Progress
in Recombinant Influenza
Vaccine Development Toward
Heterosubtypic Immune Response.
Front. Immunol. 13:948031.
doi: 10.3389/fimmu.2022.948031

¹ Pathogen-Host-Environment Interactions Research Laboratory, Institute of Biology, College of Science, University of the Philippines Diliman, Quezon City, Philippines, ² Clinical and Translational Research Institute, The Medical City, Pasig City, Philippines

Keywords: heterosubtypic immunity, influenza, influenza antigen, recombinant vaccine, universal vaccine

A Corrigendum on

Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response

By Carascal MB, Pavon RDN and Rivera WL (2022) *Front. Immunol.* 13:878943. doi: 10.3389/fimmu.2022.878943.

In the original article, there was a mistake in **Figure 4** as published. An old version of **Figure 4** was used instead of the latest figure file. The corrected **Figure 4** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Carascal, Pavon and Rivera. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.




FIGURE 4 | General construction process of recombinant protein, DNA, VLP, vector-based, and mRNA influenza vaccines.